LiteFold, founded in 2025, aims to build the "only platform a computational biologist will ever need." Their "AI co-scientist" Rosalind aims to remove the biggest bottleneck in early-stage drug discovery—software development itself. For biotech VCs, this directly impacts the unit economics of funding drug candidates.
How We Got Here
Anindyadeep Sannigrahi, an ML engineer, started building this platform in 2025 during an AI residency at Lossfunk in Bengaluru. His pivot into computational protein design followed the 2024 Nobel Prize recognizing breakthroughs in the field.
The Numbers
- Founder Anindyadeep Sannigrahi began building the platform after realizing computational biologists lack integrated development environments (IDEs).
- American computational biologist Cory Kornowicz joined LiteFold after seeing Sannigrahi's posts on X, bringing the team to five members.
- The startup operates out of Bengaluru and Delaware, focusing initially on therapeutic design with plans to expand into biological engineering.
- Their AI co-scientist, named Rosalind, allows parallel execution of hundreds of hypotheses to accelerate discovery workflows.
What Happens Next
🇮🇳 Why This Matters for India
For Bengaluru's emerging biotech founders and deep-tech engineers, LiteFold signals a growing domestic focus on foundational AI tools for complex R&D.
The Take
The real bottleneck in drug discovery isn't just generating hundreds of hypotheses; it is validating them in wet labs, which LiteFold explicitly excludes. This platform significantly moves the goalposts, but the capital expenditure for clinical trials and physical testing remains the dominant challenge.
Source:
YourStory ↗